In patients whose melanoma has progressed after treatment with ipilimumab, the monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1]. This was suggested by a phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Previously-treated advanced melanoma patients have limited options," says the study's principal investigator, Professor Jeffrey Weber, Director of the Donald A. Adam ...Tuesday, 30 September 2014
Monoclonal Antibody Nivolumab Shows Signs of Superior Response Rate in Advanced Melanoma
In patients whose melanoma has progressed after treatment with ipilimumab, the monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1]. This was suggested by a phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Previously-treated advanced melanoma patients have limited options," says the study's principal investigator, Professor Jeffrey Weber, Director of the Donald A. Adam ...
No comments:
Post a Comment